Pfizer (PFE) - Fundamental Analysis Report 2026 (Updated)
Dear Investor, Welcome to Deep Research Global.
In last week’s poll, Pfizer (PFE) received 75% of the votes. So, here’s the full fundamental analysis report…
Vote for the next week’s poll:
In case you missed it, here are the latest reports:
List of All Reports - Check It Out
Executive TL;DR
Pfizer (PFE) delivered a clean Q2 2026 beat on August 4, 2026: revenue of $15.03 billion versus roughly $14.4 billion expected, and adjusted EPS of $0.77 versus $0.68 expected, while raising full-year revenue guidance by $500 million at the midpoint.
The core business is doing the heavy lifting. Non-COVID products grew 5% operationally, and launched plus acquired products generated $3.2 billion in the quarter, up 18% operationally.
Management cut its 2026 COVID revenue assumption to about $4 billion from about $5 billion, confirming that Comirnaty and Paxlovid are fading faster than planned.
The stock carries a dividend yield near 6.4% forward, trades at a single-digit forward earnings multiple, and faces a defined patent cliff on Eliquis and other blockbusters starting in 2028, which makes the next few quarters of pipeline execution the real story.
Table of Contents
Executive TL;DR
Pfizer Company Profile: Key Facts Snapshot
The Post-COVID Baseline
How Pfizer Got Here
What the Raise Actually Signals
Pfizer Business Model Overview
How Pfizer Actually Makes Money
The Portfolio Construction Logic
Why the Business Model Is Under Stress
Pfizer Revenue Analysis
The Top Line: Flat Optics, Rotating Engine
Product-Level Drivers: Where the Growth Actually Is
COVID: Managing a Controlled Descent
Q2 FY2026 Earnings Report Analysis
Headline Results Versus Expectations
Guidance: A Raise With a Tell Inside
Earnings Quality: Reading Through the GAAP Loss
Margins and the Cost Machine
Cash Flow Mechanics
Balance Sheet Health
The Growth Cohort Math
Geographic and Seasonal Texture
EPS Trajectory: The Path Through 2027
Working Capital and One-Time Items: The Cash Quality Detail
Pfizer Segment-by-Segment Teardown
Oncology: The Crown Jewel With a Fresh Scratch
Vaccines: Prevnar Holds, Abrysvo Runs, Comirnaty Fades
Internal Medicine and Specialty Care: Eliquis, Vyndaqel, and the Migraine Problem
Seagen Integration: The Quiet Success Story
Management Bench and the CFO Transition
Half-Time Report Card: H1 2026 in Review
Manufacturing Optimization: The Underappreciated Lever
Major Pfizer Competitors
Pfizer vs. Eli Lilly: The Obesity Asymmetry
Pfizer vs. Novo Nordisk: The Bidding War Echo
Pfizer vs. Merck and Bristol-Myers: Oncology and the Cardio Clock
Pfizer vs. AstraZeneca and the Lung Cancer Question
Pfizer vs. Moderna and the Vaccine Margin Question
Pfizer Strategic Context
The Post-COVID Rebuild
The Patent Cliff Response
R&D Discipline: The August Pipeline Cleanout
Obesity: Anatomy of the $10 Billion Bet
The Dividend as Strategy, Not Just Policy
Pfizer Valuation Framework Analysis
The Income Lens
The Earnings Multiple Lens
The Cash Flow Lens
Sum-of-the-Parts: A Sanity Check on the Discount
What Would Change the Valuation Story
Bull, Base and Bear Case Scenario Analysis for Pfizer
Key Risks for Pfizer
Catalysts to Watch
The Investor’s Monitoring Checklist
The Five Numbers That Matter Each Quarter
Positioning This Within a Portfolio
Latest Analyst Price Targets
My Final Thoughts
Official Sources & Data
Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.
Pfizer Company Profile: Key Facts Snapshot
Pfizer (PFE) is one of the largest pure-play biopharmaceutical companies in the world.
After spinning off its Upjohn generics unit and divesting its consumer health joint venture interest, the company operates as a focused, science-led biopharma business organized around oncology, vaccines, inflammation and immunology, internal medicine, rare disease, and hospital products.
The company reports through a single Biopharma segment with product-level disclosure, which makes revenue quality analysis cleaner than at diversified peers.
Its commercial footprint spans more than 100 countries, and its manufacturing network remains one of the largest in the industry even after two rounds of footprint rationalization.
Pfizer key facts, as of August 2026
-------------------------------------
Ticker / exchange: PFE / NYSE
Headquarters: New York City, USA
CEO: Dr. Albert Bourla
Interim CFO (incoming): Cecile Guegan
FY2025 revenue: $62.6 billion
FY2026 revenue guidance: $60.5 - $62.5 billion
FY2026 adj. EPS guidance: $2.80 - $3.00
Shares outstanding (Q2): ~5,699 million basic
Quarterly dividend: $0.43 per share
Dividend streak: 349 consecutive quarterly dividends
Net leverage (Q2 2026): 2.7x
Total assets: ~$201 billion
Two structural facts frame everything else in this report.
First, Pfizer is a dividend machine with one of the longest uninterrupted payout streaks in big pharma.
Second, it’s a company mid-transformation, digesting the Seagen and Metsera acquisitions while stripping out nearly $10 billion of combined cost.
Those two facts pull the stock in opposite directions, and that tension is the entire investment debate.
The Post-COVID Baseline: Why 2026 Is the Pivot Year
How Pfizer Got Here
Every analysis of Pfizer in 2026 starts with the same historical arc. The company generated more than $100 billion of revenue in 2022 at the pandemic peak, with Comirnaty and Paxlovid contributing more than half.
By 2025, revenue had reset to $62.6 billion, and the stock spent three years grinding lower as the market refused to pay for earnings it believed would evaporate with the virus.
The reset created the setup that exists today.
Expectations were cut to the bone in December 2025, when the company framed 2026 revenue at $59.5 to $62.5 billion and the shares dropped 5% on the news.
From that lowered base, Pfizer has now delivered two consecutive beats, and the August raise marks the first upward revision to annual revenue guidance since the pandemic era ended.
Pfizer revenue arc
-----------------------------------
2022 (peak): >$100B total,
>$56B from COVID
2025 (reset): $62.6B total
Dec 2025 guide: $59.5B - $62.5B
Aug 2026 guide: $60.5B - $62.5B
(midpoint raised $500M)
COVID 2026E: ~$4B, down from ~$5B
What the Raise Actually Signals
Guidance raises from Pfizer have been rare enough since 2023 that this one carries information beyond its $500 million size.
Management raised the revenue floor while cutting the COVID assumption in the same breath, which means the commercial organization outperformed its own plan by roughly $1.5 billion on the non-COVID side.
Companies do not raise guidance in August unless the first-half run rate plus visible second-half orders support it.
The reaffirmed EPS range matters as much.
Holding $2.80 to $3.00 while absorbing a fresh $650 million Innovent-related charge implies the operating business is running ahead of the EPS plan too, with cost savings and gross margin doing the offsetting work. For a stock priced on skepticism, each quarter of delivery compresses the credibility discount.
Pfizer Business Model Overview
How Pfizer Actually Makes Money
Strip away the press releases and Pfizer’s economic engine is simple to describe and hard to replicate.
The company discovers or acquires patented medicines, prices them under exclusivity, defends that exclusivity through patents and litigation, and converts the resulting high gross margins into cash that funds research, deals, and dividends.
The model’s center of gravity has shifted over the past three years.
The COVID franchise that delivered more than $56 billion of combined 2022 revenue is now a roughly $4 billion assumption for 2026, and the growth engine has been rebuilt around three pillars:
The Seagen oncology platform,
The legacy in-line portfolio led by Eliquis and the Vyndaqel family, and
A set of recently launched or acquired products that management groups together as its growth cohort.
Pfizer revenue engine, 2026 structure
--------------------------------------
Pillar 1: In-line blockbusters
Eliquis (alliance share), Prevnar family,
Ibrance, Vyndaqel family
Pillar 2: Launched and acquired products
Padcev, Adcetris, Lorbrena, Nurtec/Vydura,
Abrysvo, Talzenna, Hympavzi
Q2 2026 cohort revenue: $3.2B, +18% operational
Pillar 3: COVID franchise (declining)
Comirnaty + Paxlovid
2026E: ~$4 billion (was ~$5 billion)
Funding loop:
Gross margin (adj. 76%) -> $5.5B H1 R&D
-> dividends $4.9B H1 -> BD/pipeline deals
Gross margin is the tell. At 76% adjusted, Pfizer earns economics that software companies would recognize, because patents do the work that moats do elsewhere.
The business model’s weakness is the mirror image of that strength: when exclusivity ends, the economics do not erode gently, they fall off a shelf.
The Portfolio Construction Logic
Management has been explicit about how it wants the portfolio to look by the end of the decade. The $43 billion Seagen deal in 2023 was the down payment, and Pfizer said at the time the combined oncology pipeline could produce at least eight blockbuster medicines by 2030.
Oncology now anchors the growth story because cancer drugs carry durable pricing power, strong specialist prescribing relationships, and combination-therapy economics that extend franchises.
The obesity push through Metsera is the second leg, aimed at a market where pricing and demand have both proven far stronger than legacy pharma models assumed.
Strategic intent by therapeutic area
--------------------------------------
Oncology: Scale + pipeline depth (Seagen,
Padcev, Adcetris, Braftovi combos)
Obesity: Re-entry via Metsera ($10B, 2025),
berobenatide Phase 3 in 2026
Vaccines: Prevnar defense, Abrysvo expansion,
COVID managed decline
Internal med: Eliquis cash cow -> IRA pricing
and 2028 LOE planning
Rare disease: Vyndaqel family durability,
Hympavzi label expansion
The logic is coherent: harvest the mature blockbusters while they last, and concentrate reinvestment in the two therapeutic areas with the deepest unmet need and the strongest reimbursement dynamics.
Execution risk sits in the middle, because both oncology and obesity require clinical wins that Pfizer’s recent R&D record has not always delivered.
Why the Business Model Is Under Stress
The strain comes from timing. Pfizer’s largest product, Eliquis, faces US generic entry no earlier than April 1, 2028 under the settlement framework with Bristol-Myers Squibb, and European exclusivity already expired on May 19, 2026.
Ibrance, Xtandi, and Prevnar 13 lose protection in the same window, a cluster that’s one of the steepest in the industry.
So the business model question for 2026 is not whether Pfizer can run its current portfolio well. Q2 answered that. The question is whether the replacement assets can reach commercial scale before the 2028 shelf arrives, and that’s a clinical and regulatory question, not a financial engineering one.
Pfizer Revenue Analysis
The Top Line
Pfizer guided 2026 revenue to $60.5 to $62.5 billion after raising the midpoint by $500 million in August, against $62.6 billion delivered in 2025.
On the surface that reads as a stagnant company.
Underneath, the mix is rotating fast: roughly $1.5 billion of the guidance reflects stronger non-COVID performance, while the COVID assumption dropped by $1 billion in the same quarter.
2026 guidance bridge (company disclosure)
------------------------------------------
Prior range (Dec 2025): $59.5B - $62.5B
Raised (Aug 4, 2026): $60.5B - $62.5B
Change at midpoint: +$500M
Non-COVID uplift: ~ +$1.5B expected
COVID revision: ~ -$1.0B
(COVID now ~$4B, was ~$5B)
FY2025 actual revenue: $62.6B
Implication: flat to slightly down
reported, growing ex-COVID
Ex-COVID growth is the number institutional holders watch. The underlying portfolio grew 5% operationally in Q2, and the launched-and-acquired cohort grew 18% operationally, or 27% excluding one-time items.
If those rates
Keep reading with a 7-day free trial
Subscribe to Deep Research Global to keep reading this post and get 7 days of free access to the full post archives.